LU92681I2 - Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate - Google Patents

Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate

Info

Publication number
LU92681I2
LU92681I2 LU92681C LU92681C LU92681I2 LU 92681 I2 LU92681 I2 LU 92681I2 LU 92681 C LU92681 C LU 92681C LU 92681 C LU92681 C LU 92681C LU 92681 I2 LU92681 I2 LU 92681I2
Authority
LU
Luxembourg
Prior art keywords
nintédanib
salts
esilate
tautomers
pharmaceutically acceptable
Prior art date
Application number
LU92681C
Other languages
English (en)
French (fr)
Other versions
LU92681I9 (en:Method
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92681(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/de
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of LU92681I2 publication Critical patent/LU92681I2/xx
Publication of LU92681I9 publication Critical patent/LU92681I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU92681C 1999-10-13 2015-03-16 Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate LU92681I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19949208A DE19949208A1 (de) 1999-10-13 1999-10-13 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de) 2000-08-31 2000-08-31 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (de) 1999-10-13 2000-10-09 In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
LU92681I2 true LU92681I2 (fr) 2015-05-18
LU92681I9 LU92681I9 (en:Method) 2019-01-03

Family

ID=26006858

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92681C LU92681I2 (fr) 1999-10-13 2015-03-16 Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate

Country Status (43)

Country Link
EP (2) EP1224170B9 (en:Method)
JP (2) JP4021664B2 (en:Method)
KR (2) KR100835546B1 (en:Method)
CN (1) CN100455568C (en:Method)
AR (1) AR026036A1 (en:Method)
AT (1) ATE439342T1 (en:Method)
AU (1) AU781939B2 (en:Method)
BE (1) BE2015C018I2 (en:Method)
BG (1) BG65983B1 (en:Method)
BR (1) BRPI0014735B8 (en:Method)
CA (1) CA2387013C (en:Method)
CO (1) CO5261488A1 (en:Method)
CY (2) CY1110067T1 (en:Method)
CZ (1) CZ301073B6 (en:Method)
DE (1) DE50015711D1 (en:Method)
DK (1) DK1224170T5 (en:Method)
EA (1) EA006080B1 (en:Method)
EE (1) EE05427B1 (en:Method)
EG (1) EG25931A (en:Method)
ES (1) ES2331459T3 (en:Method)
FR (1) FR15C0024I2 (en:Method)
HK (1) HK1052505B (en:Method)
HR (1) HRP20020306B1 (en:Method)
HU (2) HU230416B1 (en:Method)
IL (2) IL148756A0 (en:Method)
LT (1) LTC1224170I2 (en:Method)
LU (1) LU92681I2 (en:Method)
ME (1) MEP45408A (en:Method)
MX (1) MXPA02002799A (en:Method)
MY (1) MY127956A (en:Method)
NL (1) NL300725I2 (en:Method)
NO (3) NO322746B1 (en:Method)
NZ (1) NZ518489A (en:Method)
PE (1) PE20010671A1 (en:Method)
PL (1) PL207445B1 (en:Method)
PT (1) PT1224170E (en:Method)
RS (1) RS51013B (en:Method)
SA (1) SA01210704B1 (en:Method)
SI (1) SI1224170T1 (en:Method)
SK (1) SK287312B6 (en:Method)
TW (1) TWI268922B (en:Method)
UA (1) UA75054C2 (en:Method)
WO (1) WO2001027081A1 (en:Method)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE60126997T2 (de) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2274075T3 (es) 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
ATE345839T1 (de) 2001-06-29 2006-12-15 Ab Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
WO2003003006A2 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US7741335B2 (en) 2001-06-29 2010-06-22 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
US6765012B2 (en) * 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4363985B2 (ja) 2001-12-27 2009-11-11 セラヴァンス， インコーポレーテッド タンパク質キナーゼ阻害剤として有用なインドリン誘導体
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (it) * 2002-04-12 2003-10-13 Univ Bologna Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
JP2010529161A (ja) * 2007-06-12 2010-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インドリノン誘導体及び癌等の症状を治療する際のそれらの使用
DK2170827T3 (da) 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
RU2525114C2 (ru) * 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производного индолинона
EP2293795B1 (en) 2008-06-06 2015-08-12 Boehringer Ingelheim International GmbH Pharmaceutical combination
AU2009275964A1 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh New compounds
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
WO2011021597A1 (ja) 2009-08-19 2011-02-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体含有医薬組成物
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AU2013211888B2 (en) 2012-01-26 2017-08-31 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
HK1214831A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型融合分子及其应用
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
WO2014086102A1 (zh) 2012-12-06 2014-06-12 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
DK3524595T3 (da) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Quinolinderivat af høj renhed og fremgangsmåde til fremstilling deraf
CN104262232B (zh) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 尼泰达尼的制备方法
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
EP3302379B1 (en) 2015-06-06 2023-11-22 Cloudbreak Therapeutics, LLC Compositions and methods for treating pterygium
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 一种一锅煮法合成尼达尼布关键中间体的新方法
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
SG11201805423TA (en) 2015-12-24 2018-07-30 Respivert Ltd Indolinones compounds and their use in the treatment of fibrotic diseases
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
WO2017153748A1 (en) 2016-03-08 2017-09-14 Respivert Limited Indole derivatives and their use as protein kinase inhibitors
US20190160054A1 (en) 2016-04-13 2019-05-30 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
WO2017203027A1 (en) 2016-05-27 2017-11-30 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
MX395539B (es) 2016-07-29 2025-03-25 Oncternal Therapeutics Inc Usos de compuestos de indolinona
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
BR112020003973A2 (pt) 2017-10-23 2020-09-01 Boehringer Ingelheim International Gmbh combinação de agentes ativos para o tratamento de doenças pulmonares intersticiais fibrosantes progressivas (pf-ild)
JP7382317B2 (ja) 2017-11-17 2023-11-16 フェルミオン オサケ ユキチュア ニンテダニブを製造するための中間体として公知の２－インドリノン誘導体の合成
JP7061310B2 (ja) * 2018-04-05 2022-04-28 国立大学法人 大分大学 慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
EP3813793B1 (en) 2018-05-25 2023-09-20 ADS Therapeutics LLC A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
SG11202103459WA (en) * 2018-10-05 2021-05-28 Ichnos Sciences S A Indolinone compounds for use as map4k1 inhibitors
EP4125890A1 (en) 2020-04-01 2023-02-08 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
US20240238368A1 (en) 2021-01-25 2024-07-18 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (zh) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 一类用作激酶抑制剂的化合物及其制备方法和用途
EP4572763A1 (en) 2022-08-16 2025-06-25 Boehringer Ingelheim International GmbH Pharmaceutical formulations of nintedanib for intraocular use
TWI857798B (zh) * 2023-09-28 2024-10-01 國立臺灣大學 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96047C (en:Method) * 1956-06-08
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2214759C (en) * 1996-01-17 2004-05-18 Taiho Pharmaceutical Co., Ltd. Intimal hypertrophy inhibitors
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
PL207445B1 (pl) 2010-12-31
LTC1224170I2 (lt) 2023-11-10
JP2007302697A (ja) 2007-11-22
KR20020038949A (ko) 2002-05-24
SI1224170T1 (sl) 2009-12-31
EE05427B1 (et) 2011-06-15
AU781939B2 (en) 2005-06-23
UA75054C2 (uk) 2006-03-15
HU230416B1 (hu) 2016-05-30
WO2001027081A1 (de) 2001-04-19
FR15C0024I2 (fr) 2016-08-26
MY127956A (en) 2007-01-31
JP2003511441A (ja) 2003-03-25
BG65983B1 (bg) 2010-08-31
DE50015711D1 (de) 2009-09-24
KR20070095996A (ko) 2007-10-01
BE2015C018I2 (en:Method) 2019-10-23
HRP20020306A2 (en) 2003-10-31
SK287312B6 (sk) 2010-06-07
PE20010671A1 (es) 2001-06-28
EG25931A (en) 2012-10-24
AR026036A1 (es) 2002-12-26
CN1391557A (zh) 2003-01-15
ES2331459T3 (es) 2010-01-05
HUP0204587A2 (en) 2003-05-28
NO20021719L (no) 2002-04-11
EP1224170B9 (de) 2017-11-22
SK6462002A3 (en) 2002-08-06
PT1224170E (pt) 2009-10-01
KR100857734B1 (ko) 2008-09-10
BRPI0014735B1 (pt) 2012-07-10
EA200200380A1 (ru) 2002-10-31
ATE439342T1 (de) 2009-08-15
NO2015009I2 (en:Method) 2015-03-18
LU92681I9 (en:Method) 2019-01-03
HK1052505A1 (en) 2003-09-19
CA2387013A1 (en) 2001-04-19
BRPI0014735B8 (pt) 2021-07-06
AU1023301A (en) 2001-04-23
NO2015009I1 (no) 2015-03-30
HUS1600022I1 (hu) 2017-02-28
PL355433A1 (pl) 2004-04-19
IL148756A (en) 2007-10-31
HUP0204587A3 (en) 2004-07-28
CO5261488A1 (es) 2003-03-31
NO2023033I1 (no) 2023-09-05
IL148756A0 (en) 2002-09-12
RS51013B (sr) 2010-10-31
HK1052505B (zh) 2009-06-26
BRPI0014735A (pt) 2002-07-16
NZ518489A (en) 2005-05-27
DK1224170T3 (da) 2009-12-07
MEP45408A (en) 2011-02-10
CN100455568C (zh) 2009-01-28
NO20021719D0 (no) 2002-04-11
BG106587A (bg) 2003-01-31
EA006080B1 (ru) 2005-08-25
NL300725I2 (nl) 2017-07-13
EE200200197A (et) 2003-06-16
CA2387013C (en) 2009-12-29
FR15C0024I1 (en:Method) 2015-04-17
EP1224170B1 (de) 2009-08-12
CY2015009PI2 (el) 2016-12-14
HRP20020306B1 (en) 2010-09-30
EP2157081A1 (de) 2010-02-24
KR100835546B1 (ko) 2008-06-09
MXPA02002799A (es) 2003-02-27
CY1110067T1 (el) 2015-01-14
CZ301073B6 (cs) 2009-10-29
NO322746B1 (no) 2006-12-04
TWI268922B (en) 2006-12-21
EP1224170A1 (de) 2002-07-24
CZ20021410A3 (cs) 2002-07-17
LTPA2015015I1 (lt) 2015-04-27
JP4021664B2 (ja) 2007-12-12
YU26602A (sh) 2004-11-25
CY2015009PI1 (el) 2016-12-14
SA01210704B1 (ar) 2006-12-05
DK1224170T5 (en) 2018-01-22

Similar Documents

Publication Publication Date Title
LU92681I2 (fr) Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
LU91363I2 (fr) Méthoxy polyéthylène glycol-époétine bêta et ses sels pharmaceutiquement acceptables (MIRCERA)
LU91650I2 (fr) Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
DE60139964D1 (de) Bakterielle Gyrase-Hemmer sowie deren Verwendung
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
DK1177178T3 (da) Heterocyclisk substituerede benzimidazoler, deres fremstilling og anvendelse
MXPA03005923A (es) Derivados de glupopiranosiloxipirazol y su uso en medicinas.
NO2008001I1 (no) Vildagliptin og farmasoytisk akseptable salter derav
SI1326862T1 (sl) Kristalinični monohidrat tiotropijevega bromida, postopek za njegovo pripravo in njegova uporaba za pripravo zdravila
ZA200202479B (en) Heterocyclic sodium/proton exchange inhibitors and method.
NO2011002I2 (no) Regadenoson og salter derav
NO20025227L (no) Tropanderivater nyttige i terapi
MXPA03005713A (es) Derivados de tetrahidropiridina, su preparacion y su uso como inhibidores de proliferacion celular.
PL356427A1 (en) Indol-3-yl derivatives and their use as integrin inhibitors
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
DE60023642D1 (de) Walzwerk
AU5066900A (en) Benzimidazole derivatives and their use as methionyl t-rna synthetase inhibitors
NO2005007I2 (no) Pemetrexed og farmasoytisk akseptable salter derav
NO20015897D0 (no) Indolylpiperidinderivater som antihistaminiske og antiallergiske midler
NO20024598L (no) Farmasöytisk aktive pyrrolidinderivater
NO20016419D0 (no) Melagatran i vesentlig krystallinsk form
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors